Browse Category

NASDAQ:TEM News 8 October 2025 - 6 December 2025

Tempus AI (TEM) Stock: FDA Wins, Q3 Earnings, and Analyst Forecasts – December 6, 2025

Tempus AI (TEM) Stock: FDA Wins, Q3 Earnings, and Analyst Forecasts – December 6, 2025

Updated: December 6, 2025 Tempus AI Inc. (NASDAQ: TEM) has quickly become one of the most closely watched artificial intelligence stocks in healthcare. After a year marked by multiple FDA clearances, strong revenue growth and high-profile partnerships, Wall Street is now debating whether the current share price in the mid‑$70s still leaves meaningful upside. Business Wire+1 Fresh research notes and news items published on December 5–6, 2025—including new institutional buying, updated growth forecasts and a cluster of analyst price targets—are reshaping the conversation around the stock’s outlook heading into 2026. MarketBeat+2Nasdaq+2 Tempus AI at a glance Tempus AI is a
Tempus AI (TEM) Stock Skyrockets on AI Healthcare Breakthroughs – Inside the Price Surge, Latest News & 2025 Outlook

Tempus AI (TEM) Stock Skyrockets on AI Healthcare Breakthroughs – Inside the Price Surge, Latest News & 2025 Outlook

Stock Price Surge: From IPO to Record Highs Tempus AI’s stock has been on a remarkable tear since its mid-2024 IPO. The Chicago-based healthtech firm – founded in 2015 by Eric Lefkofsky (of Groupon fame) – went public in June 2024 at around $21 per share, and the price has since quadrupled ts2.tech. After a steady climb through 2024, momentum accelerated in 2025 as the company delivered strong results and AI breakthroughs. By early September 2025, TEM had more than doubled its IPO price, reaching the high-$80s to $90 range ts2.tech. A series of catalysts (detailed below) then propelled the
9 October 2025
Tempus AI (TEM) Stock Skyrockets on AI Healthcare Breakthroughs – What Investors Need to Know

Tempus AI (TEM) Stock Skyrockets on AI Healthcare Breakthroughs – What Investors Need to Know

Company Overview and Mission Tempus AI, Inc. is an American health technology company founded in 2015 by entrepreneur Eric Lefkofsky (best known as co-founder of Groupon). Headquartered in Chicago, Tempus was born from Lefkofsky’s personal mission to improve cancer care after his wife’s battle with breast canceren.wikipedia.org. The company’s core focus is on applying AI and data analytics to personalized medicine. Tempus has built what it calls an “operating system” for healthcare: a platform that ingests vast amounts of clinical and molecular data (gene sequences, lab tests, medical records, imaging, etc.) and makes it accessible for treatment decisions and researchinsidermonkey.com. Its goal is to enable doctors and

Stock Market Today

AMD stock rebounds 8% after post-earnings slump as payrolls, CPI loom

AMD stock rebounds 8% after post-earnings slump as payrolls, CPI loom

7 February 2026
New York, Feb 7, 2026, 14:17 ET — Market closed. Advanced Micro Devices (AMD.O) shares finished Friday up 8.2% at $208.44, recovering some ground after a volatile week that punished chipmakers on guidance and AI competition worries. The snapback matters because AMD’s midweek slide showed how quickly the market is willing to reprice “AI winners” when the outlook does not clear a high bar. With U.S. data now set to land in a bunch next week, traders are also bracing for fresh swings in rate-cut bets that tend to hit growth stocks first. Friday’s move came as chip stocks led
Netflix stock price ends higher as DOJ widens review of Warner deal — what to watch next week

Netflix stock price ends higher as DOJ widens review of Warner deal — what to watch next week

7 February 2026
Netflix shares rose 1.6% to $82.20 Friday as the Justice Department expanded its antitrust review of the company’s planned $82.7 billion Warner Bros Discovery acquisition. A Wall Street Journal report said investigators are probing possible anti-competitive tactics. Director Reed Hastings reported a transfer of 241,944 shares via a family trust, according to an SEC filing.
Go toTop